Patient Perspectives on Switching from Infliximab to Infliximab‐dyyb in Patients with Rheumatologic Diseases in the United States

OBJECTIVE: The introduction of biosimilars for rheumatologic diseases (RDs) has provided a potentially lower‐cost therapy compared with their bio‐originator products; however, adoption of biosimilars may be challenged by patient perceptions. The objective of this study was to describe patients’ pers...

Descripción completa

Detalles Bibliográficos
Autores principales: Chau, Jason, Delate, Thomas, Ota, Taylor, Bhardwaja, Bharati
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6858025/
https://www.ncbi.nlm.nih.gov/pubmed/31777780
http://dx.doi.org/10.1002/acr2.1007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6858025/
https://www.ncbi.nlm.nih.gov/pubmed/31777780
http://dx.doi.org/10.1002/acr2.1007

Ejemplares similares